New medical therapies on the horizon: oral octreotide View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-01-16

AUTHORS

Nienke R. Biermasz

ABSTRACT

Somatostatin analog treatment is first line medical treatment in patients with acromegaly. This drug is currently mainly administered by monthly depot preparations of octreotide and lanreotide. With the innovative transient permeability enhancer, a technology enabling the absorption of drug molecules via transient opening of the tight junctions of the gut epithelium, it is possible to achieve therapeutic octreotide levels after oral ingestion. The present review summarized the preclinical work and the recently reported phase I and III study on oral octreotide capsules in patients with acromegaly. Maintenance of control in 155 participating patients was achieved in 65% at the end of core period. Once controlled on oral octreotide, the response was maintained to the end of the extension phase in 85%. Side effects were comparable to currently available preparations. There was a profound suppression of growth hormone levels, and significant symptom reduction. Currently available parental somatostatin analogs are generally well tolerated and are able to achieve longstanding biochemical control in patients with somatostatin sensitive tumors. Potential advantages of an oral alternative is the lack injection-related side effects, but there will be an ongoing need for a very strict compliance with the 2 daily dose regimen and fasting around drug administrations. A second phase III study is currently being conducted. The potential place in the treatment of acromegaly is discussed. More... »

PAGES

149-153

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11102-016-0785-3

DOI

http://dx.doi.org/10.1007/s11102-016-0785-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1052153091

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28091879


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acromegaly", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Octreotide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pituitary Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Somatostatin", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology, Department of Internal Medicine, Leiden University Medical Center, BOX 9600, 2300, RC Leiden, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.10419.3d", 
          "name": [
            "Division of Endocrinology, Department of Internal Medicine, Leiden University Medical Center, BOX 9600, 2300, RC Leiden, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Biermasz", 
        "givenName": "Nienke R.", 
        "id": "sg:person.0744212346.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744212346.10"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11102-015-0681-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013538559", 
          "https://doi.org/10.1007/s11102-015-0681-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrendo.2015.196", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020354429", 
          "https://doi.org/10.1038/nrendo.2015.196"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00544562", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021493467", 
          "https://doi.org/10.1007/bf00544562"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrendo.2014.21", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044514265", 
          "https://doi.org/10.1038/nrendo.2014.21"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11102-015-0684-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051359339", 
          "https://doi.org/10.1007/s11102-015-0684-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11095-014-1303-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008322572", 
          "https://doi.org/10.1007/s11095-014-1303-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-01-16", 
    "datePublishedReg": "2017-01-16", 
    "description": "Somatostatin analog treatment is first line medical treatment in patients with acromegaly. This drug is currently mainly administered by monthly depot preparations of octreotide and lanreotide. With the innovative transient permeability enhancer, a technology enabling the absorption of drug molecules via transient opening of the tight junctions of the gut epithelium, it is possible to achieve therapeutic octreotide levels after oral ingestion. The present review summarized the preclinical work and the recently reported phase I and III study on oral octreotide capsules in patients with acromegaly. Maintenance of control in 155 participating patients was achieved in 65% at the end of core period. Once controlled on oral octreotide, the response was maintained to the end of the extension phase in 85%. Side effects were comparable to currently available preparations. There was a profound suppression of growth hormone levels, and significant symptom reduction. Currently available parental somatostatin analogs are generally well tolerated and are able to achieve longstanding biochemical control in patients with somatostatin sensitive tumors. Potential advantages of an oral alternative is the lack injection-related side effects, but there will be an ongoing need for a very strict compliance with the 2 daily dose regimen and fasting around drug administrations. A second phase III study is currently being conducted. The potential place in the treatment of acromegaly is discussed.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11102-016-0785-3", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1119029", 
        "issn": [
          "1386-341X", 
          "1573-7403"
        ], 
        "name": "Pituitary", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "keywords": [
      "side effects", 
      "injection-related side effects", 
      "second phase III study", 
      "first-line medical treatment", 
      "oral octreotide capsules", 
      "daily dose regimen", 
      "somatostatin analogue treatment", 
      "phase III study", 
      "treatment of acromegaly", 
      "growth hormone levels", 
      "significant symptom reduction", 
      "new medical therapies", 
      "oral octreotide", 
      "dose regimen", 
      "III study", 
      "medical therapy", 
      "oral alternative", 
      "octreotide levels", 
      "depot preparation", 
      "somatostatin analogues", 
      "sensitive tumors", 
      "analogue treatment", 
      "profound suppression", 
      "hormone levels", 
      "oral ingestion", 
      "preclinical work", 
      "medical treatment", 
      "symptom reduction", 
      "biochemical control", 
      "Drug Administration", 
      "patients", 
      "acromegaly", 
      "gut epithelium", 
      "extension phase", 
      "phase I", 
      "available preparations", 
      "tight junctions", 
      "treatment", 
      "present review", 
      "ongoing need", 
      "permeability enhancers", 
      "maintenance of control", 
      "core period", 
      "transient opening", 
      "strict compliance", 
      "regimen", 
      "octreotide", 
      "lanreotide", 
      "potential place", 
      "therapy", 
      "tumors", 
      "administration", 
      "epithelium", 
      "ingestion", 
      "drugs", 
      "potential advantages", 
      "levels", 
      "control", 
      "study", 
      "capsule", 
      "effect", 
      "drug molecules", 
      "review", 
      "compliance", 
      "suppression", 
      "response", 
      "period", 
      "enhancer", 
      "end", 
      "preparation", 
      "reduction", 
      "maintenance", 
      "junction", 
      "need", 
      "analogues", 
      "alternative", 
      "opening", 
      "molecules", 
      "absorption", 
      "phase", 
      "place", 
      "advantages", 
      "work", 
      "technology", 
      "horizon"
    ], 
    "name": "New medical therapies on the horizon: oral octreotide", 
    "pagination": "149-153", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1052153091"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11102-016-0785-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28091879"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11102-016-0785-3", 
      "https://app.dimensions.ai/details/publication/pub.1052153091"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_737.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11102-016-0785-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11102-016-0785-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11102-016-0785-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11102-016-0785-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11102-016-0785-3'


 

This table displays all metadata directly associated to this object as RDF triples.

198 TRIPLES      21 PREDICATES      123 URIs      109 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11102-016-0785-3 schema:about N1f01f37f1ea44fb185e193e5628cb8c0
2 N21d2d2a8921e47f3a4d728251f235ec7
3 N39b35b4bb1ae411fab13532bb6347a1d
4 N5222617bd34b43a59eb180b58f6005d6
5 N5a6bb1cbab094d29b92b86dc5b638617
6 N8cc003cf6b894cf69e10009fbaf5dfed
7 N985f9cfaeb4944cd9b70b6cf41c3a19d
8 anzsrc-for:11
9 anzsrc-for:1115
10 schema:author N121293abdd424646b1176abede998576
11 schema:citation sg:pub.10.1007/bf00544562
12 sg:pub.10.1007/s11095-014-1303-9
13 sg:pub.10.1007/s11102-015-0681-2
14 sg:pub.10.1007/s11102-015-0684-z
15 sg:pub.10.1038/nrendo.2014.21
16 sg:pub.10.1038/nrendo.2015.196
17 schema:datePublished 2017-01-16
18 schema:datePublishedReg 2017-01-16
19 schema:description Somatostatin analog treatment is first line medical treatment in patients with acromegaly. This drug is currently mainly administered by monthly depot preparations of octreotide and lanreotide. With the innovative transient permeability enhancer, a technology enabling the absorption of drug molecules via transient opening of the tight junctions of the gut epithelium, it is possible to achieve therapeutic octreotide levels after oral ingestion. The present review summarized the preclinical work and the recently reported phase I and III study on oral octreotide capsules in patients with acromegaly. Maintenance of control in 155 participating patients was achieved in 65% at the end of core period. Once controlled on oral octreotide, the response was maintained to the end of the extension phase in 85%. Side effects were comparable to currently available preparations. There was a profound suppression of growth hormone levels, and significant symptom reduction. Currently available parental somatostatin analogs are generally well tolerated and are able to achieve longstanding biochemical control in patients with somatostatin sensitive tumors. Potential advantages of an oral alternative is the lack injection-related side effects, but there will be an ongoing need for a very strict compliance with the 2 daily dose regimen and fasting around drug administrations. A second phase III study is currently being conducted. The potential place in the treatment of acromegaly is discussed.
20 schema:genre article
21 schema:isAccessibleForFree true
22 schema:isPartOf N0ec632482eb745d7ad462c950e0d9b82
23 N68dda82208a64885b993cb783c34176c
24 sg:journal.1119029
25 schema:keywords Drug Administration
26 III study
27 absorption
28 acromegaly
29 administration
30 advantages
31 alternative
32 analogue treatment
33 analogues
34 available preparations
35 biochemical control
36 capsule
37 compliance
38 control
39 core period
40 daily dose regimen
41 depot preparation
42 dose regimen
43 drug molecules
44 drugs
45 effect
46 end
47 enhancer
48 epithelium
49 extension phase
50 first-line medical treatment
51 growth hormone levels
52 gut epithelium
53 horizon
54 hormone levels
55 ingestion
56 injection-related side effects
57 junction
58 lanreotide
59 levels
60 maintenance
61 maintenance of control
62 medical therapy
63 medical treatment
64 molecules
65 need
66 new medical therapies
67 octreotide
68 octreotide levels
69 ongoing need
70 opening
71 oral alternative
72 oral ingestion
73 oral octreotide
74 oral octreotide capsules
75 patients
76 period
77 permeability enhancers
78 phase
79 phase I
80 phase III study
81 place
82 potential advantages
83 potential place
84 preclinical work
85 preparation
86 present review
87 profound suppression
88 reduction
89 regimen
90 response
91 review
92 second phase III study
93 sensitive tumors
94 side effects
95 significant symptom reduction
96 somatostatin analogue treatment
97 somatostatin analogues
98 strict compliance
99 study
100 suppression
101 symptom reduction
102 technology
103 therapy
104 tight junctions
105 transient opening
106 treatment
107 treatment of acromegaly
108 tumors
109 work
110 schema:name New medical therapies on the horizon: oral octreotide
111 schema:pagination 149-153
112 schema:productId N426bfdea999f4dfd91ca709a1f6e3f3f
113 N50c6641475784206afdcd78070348aa6
114 N5209761e25364abc9a0f6643a84e986e
115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052153091
116 https://doi.org/10.1007/s11102-016-0785-3
117 schema:sdDatePublished 2022-12-01T06:36
118 schema:sdLicense https://scigraph.springernature.com/explorer/license/
119 schema:sdPublisher N9940c295de354d1cb038f9e752f1cde1
120 schema:url https://doi.org/10.1007/s11102-016-0785-3
121 sgo:license sg:explorer/license/
122 sgo:sdDataset articles
123 rdf:type schema:ScholarlyArticle
124 N0ec632482eb745d7ad462c950e0d9b82 schema:volumeNumber 20
125 rdf:type schema:PublicationVolume
126 N121293abdd424646b1176abede998576 rdf:first sg:person.0744212346.10
127 rdf:rest rdf:nil
128 N1f01f37f1ea44fb185e193e5628cb8c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Acromegaly
130 rdf:type schema:DefinedTerm
131 N21d2d2a8921e47f3a4d728251f235ec7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Octreotide
133 rdf:type schema:DefinedTerm
134 N39b35b4bb1ae411fab13532bb6347a1d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Female
136 rdf:type schema:DefinedTerm
137 N426bfdea999f4dfd91ca709a1f6e3f3f schema:name dimensions_id
138 schema:value pub.1052153091
139 rdf:type schema:PropertyValue
140 N50c6641475784206afdcd78070348aa6 schema:name doi
141 schema:value 10.1007/s11102-016-0785-3
142 rdf:type schema:PropertyValue
143 N5209761e25364abc9a0f6643a84e986e schema:name pubmed_id
144 schema:value 28091879
145 rdf:type schema:PropertyValue
146 N5222617bd34b43a59eb180b58f6005d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Humans
148 rdf:type schema:DefinedTerm
149 N5a6bb1cbab094d29b92b86dc5b638617 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Pituitary Neoplasms
151 rdf:type schema:DefinedTerm
152 N68dda82208a64885b993cb783c34176c schema:issueNumber 1
153 rdf:type schema:PublicationIssue
154 N8cc003cf6b894cf69e10009fbaf5dfed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Receptors, Somatostatin
156 rdf:type schema:DefinedTerm
157 N985f9cfaeb4944cd9b70b6cf41c3a19d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Male
159 rdf:type schema:DefinedTerm
160 N9940c295de354d1cb038f9e752f1cde1 schema:name Springer Nature - SN SciGraph project
161 rdf:type schema:Organization
162 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
163 schema:name Medical and Health Sciences
164 rdf:type schema:DefinedTerm
165 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
166 schema:name Pharmacology and Pharmaceutical Sciences
167 rdf:type schema:DefinedTerm
168 sg:journal.1119029 schema:issn 1386-341X
169 1573-7403
170 schema:name Pituitary
171 schema:publisher Springer Nature
172 rdf:type schema:Periodical
173 sg:person.0744212346.10 schema:affiliation grid-institutes:grid.10419.3d
174 schema:familyName Biermasz
175 schema:givenName Nienke R.
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744212346.10
177 rdf:type schema:Person
178 sg:pub.10.1007/bf00544562 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021493467
179 https://doi.org/10.1007/bf00544562
180 rdf:type schema:CreativeWork
181 sg:pub.10.1007/s11095-014-1303-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008322572
182 https://doi.org/10.1007/s11095-014-1303-9
183 rdf:type schema:CreativeWork
184 sg:pub.10.1007/s11102-015-0681-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013538559
185 https://doi.org/10.1007/s11102-015-0681-2
186 rdf:type schema:CreativeWork
187 sg:pub.10.1007/s11102-015-0684-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1051359339
188 https://doi.org/10.1007/s11102-015-0684-z
189 rdf:type schema:CreativeWork
190 sg:pub.10.1038/nrendo.2014.21 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044514265
191 https://doi.org/10.1038/nrendo.2014.21
192 rdf:type schema:CreativeWork
193 sg:pub.10.1038/nrendo.2015.196 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020354429
194 https://doi.org/10.1038/nrendo.2015.196
195 rdf:type schema:CreativeWork
196 grid-institutes:grid.10419.3d schema:alternateName Division of Endocrinology, Department of Internal Medicine, Leiden University Medical Center, BOX 9600, 2300, RC Leiden, The Netherlands
197 schema:name Division of Endocrinology, Department of Internal Medicine, Leiden University Medical Center, BOX 9600, 2300, RC Leiden, The Netherlands
198 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...